GlassScriptPhysician profile
Kirk Y Chang
NPI 1215924105
$13,561.98
in general payments reported to CMS, 2019-2025
50 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $1,332 · 2021: $2,646 · 2022: $1,753 · 2023: $1,945 · 2024: $1,876 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,554.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,919.58 | 2019-2025 | |
| Amgen INC. | $1,667.61 | 2019-2025 | Repatha, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,049.04 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Edwards Lifesciences Corporation | $884.67 | 2019-2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $770.13 | 2019-2023 | |
| Pfizer INC. | $699.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.87 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $573.93 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $504.27 | 2019-2022 | |
| Novo Nordisk INC | $446.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $440.70 | 2019-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $340.91 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $298.32 | 2019-2024 | Amvuttra |
| Boston Scientific Corporation | $269.46 | 2019-2025 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $263.17 | 2019-2023 | Evkeeza |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.